MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.11
-0.24
-1.31%
Opening 13:17 02/27 EST
OPEN
18.14
PREV CLOSE
18.35
HIGH
18.30
LOW
17.05
VOLUME
1.29M
TURNOVER
--
52 WEEK HIGH
21.93
52 WEEK LOW
3.520
MARKET CAP
1.94B
P/E (TTM)
-26.2997
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AUPH and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AUPH stock price target is 25.43 with a high estimate of 32.00 and a low estimate of 20.00.

EPS

AUPH News

More
  • Aurinia Appoints Max Colao as Chief Commercial Officer and Expands U.S. Commercial Leadership Team
  • Business Wire · 2d ago
  • Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference
  • Business Wire · 5d ago
  • Aurinia: A New Equilibrium
  • Seeking Alpha - Article · 02/11 11:26
  • 3 Canadian Biotechs to Consider Buying Today
  • MotleyFool.com · 02/07 12:00

Industry

Biotechnology & Medical Research
-0.89%
Pharmaceuticals & Medical Research
-0.29%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About AUPH

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.
More

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.